Conjugate Vaccine Market Growth Outlook Through 2024-2033

Overview and Scope
Conjugate vaccines, also known as immunogen conjugates, are advanced immune system modulators widely employed to develop protection against invading pathogens or make particular antibodies against the target molecule. The conjugation process enhances the immune response and allows for a more effective immune system recognition of the pathogen.

Sizing and Forecast
The conjugate vaccine market size has grown rapidly in recent years. It will grow from $16.77 billion in 2023 to $19.11 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to disease burden, government immunization programs, increased awareness, pediatric vaccination emphasis, preventive healthcare trends..

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $30.65 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to expanding immunization policies, aging population dynamics, new vaccine indications, global health security concerns, international collaboration, economic development impact. Major trends in the forecast period include collaborations and partnerships for vaccine distribution, tailored approaches for high-risk populations, application in emerging infectious diseases, advancements in vaccine manufacturing technologies, global health initiatives for vaccine equity..

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

Segmentation & Regional Insights
The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

North America was the largest region in the global conjugate vaccine market in 2023. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample_request?id=10850&type=smp
Major Driver Impacting Market Growth
The increase in the use of conjugate vaccines for adults is expected to propel the growth of the conjugate vaccine market. Conjugate vaccines are designed to stimulate a strong immune response against bacterial capsular polysaccharides, enhancing the body’s defense mechanism against bacterial infections. The use of conjugate vaccines in adults helps reduce the risk of severe illness, complications, and transmission of these bacterial diseases by stimulating a robust immune response. For instance, according to the Historical national influenza vaccination coverage 2020-2022, published by the National Centre for Immunization Research and Surveillance, an Australia-based research organization, historical influenza vaccine coverage at the end of 2022 by 15 – < 50 years age group was 29.5%, an increase from 22.8% recorded in 2021. Therefore, the increase in the use of conjugate vaccines for adults is driving the growth of the conjugate vaccine market.

Key Industry Players
Major companies operating in the conjugate vaccine market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., AstraZeneca PLC, Johnson & Johnson, Moderna Inc., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Inovio Pharmaceuticals Inc., Medicago Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

The conjugate vaccine market report table of contents includes:

1. Executive Summary

2. Conjugate Vaccine Market Characteristics

3. Conjugate Vaccine Market Trends And Strategies

4. Conjugate Vaccine Market – Macro Economic Scenario

5. Global Conjugate Vaccine Market Size and Growth
.
.
.

31. Global Conjugate Vaccine Market Competitive Benchmarking

32. Global Conjugate Vaccine Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Conjugate Vaccine Market

34. Conjugate Vaccine Market Future Outlook and Potential Analysis

35. Appendix

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model